Published in final edited form as:

Eur Urol. 2019 January ; 75(1): 42–43. doi:10.1016/j.eururo.2018.09.027.

Is ADT “Another Deficient Therapy” for Gleason Score 9-10 Prostate Cancer?

Matthew P. Deek, MD^{1,+}, Ryan M. Phillips, MD,PhD^{1,+}, Michael Haffner, MD,PhD^{2,3}, and Phuoc T. Tran, MD PhD^{1,3,4,#}

¹ Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

² Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

³ The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD

⁴ The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD

Approximately 160,000 new cases of prostate cancer are diagnosed per year in the United States (US), the majority of which are cured. However, approximately 30,000 men die each year in the US of metastatic castrate resistant prostate cancer (mCRPC) of which upwards of half began as localized or locally advanced disease. Thus, improvements in primary definitive management of these men can have a significant effect on mortality.

In this month’s issue of European Urology, Yang and colleagues report on the association between androgen deprivation therapy (ADT) and overall survival (OS) in Gleason score (GS) 8 versus GS 9–10 prostate cancer using the National Cancer Database (NCDB). [1] Their findings suggest that GS 9–10 disease is less sensitive to ADT and its use in combination with radiation therapy (RT) is not associated with improved OS. These results add to mounting evidence suggesting Gleason pattern 5 disease is resistant to conventional ADT (cADT). Dr. Anthony D’Amico first astutely observed that phase III trials assessing long term cADT in combination with radiation for localized high-risk and locally advanced prostate cancer failed to show an OS benefit when higher proportions of men with GS 9–10 prostate cancer were enrolled and suggested inherent resistance of Gleason pattern 5 to cADT in combination with radiation. [2] Huynh et al. subsequently noted worse all cause and prostate cancer specific survival (PCSS) in men with GS 5+3 or 3+5 vs 4+4 disease treated using RT and cADT. [3]

The realization that GS 8–10 disease represents an overly heterogeneous population led to the development of a “very high-risk” (VHR) group which includes primary pattern Gleason

CORRESPONDENCE: Phuoc T. Tran, Department of Radiation Oncology & Molecular Radiation Sciences, 1550 Orleans Street, CRB2 Rm 406, Baltimore, MD 21231 (phone: 410-614-3880; fax: 410-502-1419; tranp@jhmi.edu).

+ [†]Equal contribution

CONFLICT OF INTEREST

PTT co-owns the patent “Compounds and Methods of Use in Ablative Radiotherapy” (patent#: 9114158). PTT receives institutional research support from Medivation Inc-Astellas Pharma and and RefleXion Medical and has consulted for RefleXion Medical.

5. It is now well established that failure of either surgery or radiotherapy occurs more frequently in VHR disease. [4] In addition, the Pathologic Grading System of the International Society of Urological Pathology has separated GS 8 [Grade Group (GG) 4] and GS 9–10 (GG 5) disease as distinct entities, a change that has been validated. [5]

Are there additional treatment data that agree with Yang et al.? In a retrospective, multicenter cohort of GS 9–10 disease, Kishan and colleagues found significant improvements in PCSS and distant metastasis with combination external beam radiotherapy (EBRT)-brachytherapy compared to EBRT alone or radical prostatectomy but, importantly, no differences in outcomes when stratifying by use of cADT. In fact the men treated with combined EBRT-brachytherapy were treated with only an average of 12-months of cADT versus 21.9-months for the EBRT patients and still had better outcomes [6] Similarly, Sandler and colleagues reported an improvement in distant metastasis among men harboring GS 10 disease treated with EBRT-brachytherapy plus cADT as compared to EBRT plus cADT. [7] These data suggest Gleason pattern 5 disease may be less radiosensitized than lower grade disease and that physical dose escalation may be able to overcome this insensitivity to cADT.

The biological explanation for the potential insensitivity of Gleason pattern 5 disease to cADT, however, remains unknown. From a histomorphological standpoint, there is no clear evidence to support why Gleason pattern 5 disease should be resistant to cADT, however the dedifferentiated phenotype completely lacking morphological features reminiscent of benign prostate glands in pattern 5 could indicate a general loss of dependence on signaling pathways relevant to the prostate lineage such as the androgen receptor (AR). In fact, there does appear to be a group of high grade lesions with reduced AR dependence and signaling output --characterized by low PSA values, lower PCSS and associated with neuroendocrine features. [8] Genetically, there is strong evidence to suggest GG 5 tumors have a higher level of genomic instability with an increased rate of copy-number alterations and alterations in key signaling pathways (*TP53*, *PTEN* and *RBI*) that have been associated with resistance to ADT. [9] In particular, alterations in *TP53* are strongly enriched in pattern 5 lesions and have been shown to be associated with rapid progression to castration resistance. [10] Related to these genomic alterations, it may also be that Gleason pattern 5 disease more rapidly achieves castrate-resistance or that the presence of GS 9–10 disease at diagnosis is a surrogate for more rapidly progressive disease which is also more likely to have disseminated microscopically. Investigation of time to castrate resistance, time to distant metastasis, stratifying men with GS 8 into 4+4 vs 3+5/5+3 and correlation with advanced imaging modalities like PSMA-based PET will be critical to understanding the nature of this important clinical problem. Equally contributory would be studies that further profile the genomic landscape of Gleason pattern 5 disease, understanding that obtaining sufficient patients for these endeavors likely require a large, multi-institutional effort.

The accumulating evidence of cADT resistance in GS 9–10 disease now begs the question: what are the best strategies to treat these men? Answering this question in a randomized fashion will be challenging, given the rarity of the disease. The relatively low rates of biochemical progression-free survival following treatment of these men highlight the need for further testing of radiation dose escalation, supra-castration and chemohormonal

approaches to treat Gleason pattern 5 primary tumor as well as target possible metastatic clones. The work by Yang et al. generates many additional novel questions for men with GS 9–10 disease. There is clearly a need to explore better therapeutic options and importantly, genetically profile Gleason pattern 5 disease to allow for precision medicine approaches in the hopes of improving cancer specific outcomes.

FUNDING ACKNOWLEDGEMENTS

PTT was supported by the Nesbitt-McMaster Foundation, Ronald Rose & Joan Lazar; Movember Foundation, Prostate Cancer Foundation; Commonwealth Foundation; NIH/NCI (R01CA166348, U01CA212007, U01CA231776 and 1R21CA223403).

REFERENCES

1. Yang DD, et al., Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer. *Eur Urol*, (in press).
2. D'Amico AV, Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy? *Eur Urol*, 2016 69(5): p. 761–3. [PubMed: 26364550]
3. Huynh MA, et al., Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death. *Eur Urol*, 2016 69(6): p. 976–9. [PubMed: 26388503]
4. Narang AK, et al., Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. *Int J Radiat Oncol Biol Phys*, 2016 94(2): p. 254–62. [PubMed: 26853334]
5. Epstein JI, et al., A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. *Eur Urol*, 2016 69(3): p. 428–35. [PubMed: 26166626]
6. Kishan AU, et al., Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9–10 Prostate Cancer. *JAMA*, 2018 319(9): p. 896–905. [PubMed: 29509865]
7. Sandler KA, et al., Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. *Int J Radiat Oncol Biol Phys*, 2018 101(4): p. 883–888. [PubMed: 29976500]
8. Mahal BA, et al., Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. *Eur Urol*, 2018 74(2): p. 146–154. [PubMed: 29478736]
9. Robinson D, et al., Integrative clinical genomics of advanced prostate cancer. *Cell*, 2015 161(5): p. 1215–1228. [PubMed: 26000489]
10. Guedes LB, et al., Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. *Clin Cancer Res*, 2017 23(16): p. 4693–4703. [PubMed: 28446506]